A panel of advisers convened by the Food and Drug Administration (FDA) February 22 voted 20-2 to approve the weight-loss drug Qnexa, a controlled-release combination of phentermine and topiramate, being developed by Vivus. The FDA previously rejected Qnexa due to safety concerns, but scheduled a review by the Endocrinologic and Metabolic Drugs ...[Read More]